23 April 2023 in Russian Journal of Archive of Pathology
Anti-angiogenic drugs are used as an established approach of malignant neoplasms therapy. It has been established that the development of the phenomenon of vasculogenic mimicry — a specific variant of tumor neoangiogenesis, which is formed in highly aggressive solid tumors, is associated with a decrease in the effectiveness of antitumor therapy. This review highlights the mechanisms of development of vasculogenic mimicry in malignant neoplasms, which is one of the alternative options for tumor blood supply. In the formation of vasculogenic mimicry, an important role is assigned to the tumor microenvironment, primarily tumor-associated macrophages and fibroblasts. The signaling pathways that regulate the formation of vasculogenic mimicry channels in tumors have been characterized. The prospects for a targeted impact on molecular targets that initiate and promote vasculogenic mimicry, the impact on which can increase the effectiveness of antitumor therapy, are shown. The review discusses experimental studies of the mechanisms of vasculogenic mimicry formation in malignant neoplasms and the prospects for targeted action on molecules that are components of signaling cascades involved in the development of this model of neoangiogenesis.
8 March 2023 in Russian Journal of Oncology
BACKGROUND: Cellular senescence is a stress response, triggered by various stimuli such as chemotherapy treatment and causes G0/G1 cell cycle arrest followed by the production of a senescence associated secretory phenotype. p53 considered to be a modulator of these events although the precise mechanisms of it remains not clear. AIMS: To determine the non-apoptotic functions of the p53 protein the formation of the senescence associated secretory phenotype phenotype of melanoma cells under the treatment of the cytostatic agent dacarbazine. MATERIALS AND METHODS: The study was conducted on BRO and SK-MEL-2 skin melanoma cell lines. Melanoma cells were were treated by cytostatic agent dacarbazine. Then immunocytochemical study was performed to determine the proportion of G0-positive cells and the expression of the tumor suppressor protein p53. A bioinformatic analysis was accomplished to identify for p53 regulators with determining of miR-155-5p levels in exosomes released by dacarbazine-treated melanoma cells. RESULTS: The cytostatic drug dacarbazine increases the proportion of cells residing in the G0 phase of the cell cycle. Onco-microRNA miR-155-5p was expressed in the exosomes of the two studied cell lines BRO and SK-MEL-2 of skin melanoma. Changes in the expression level of p53 correlate with changes in miR-155-5p microRNA expression. The absence of changes in p53 expression in BRO melanoma cells may be due to the absence of changes in miR-155-5p expression levels. In the BRO cell line, no changes in the expression of the oncosuppressor p53 were observed with an increased percentage of G0-positive cells, which may be associated with the activation of other mechanisms of cell cycle arrest in the G0/G1 phase. CONCLUSIONS: Heterogeneous effect of the cytostatic agent dacarbazine on melanoma cells was revealed. For the SK-MEL-2 cell line, dacarbazine induces the release of senescence associated secretory phenotype by inhibiting exosomal production of miR-155-5p, which activates the p53 oncosuppressor, which was not observed in the BRO line.
1 January 2020 in Молекулярная медицина
29 June 2022 in Siberian journal of oncology
Objective. To evaluate anti-tumor, toxic effect of miR-204-5p mimic applicaton on melanoma B-16-bearing mice followed by miR-204-5p target gene expression estimation in melanoma tumor and distant organs. Material and Methods. C57Bl/6 melanoma B-16-bearing mice were used. The animals of the experimental group were intraperitoneally injected with a 5 nM miR-204-5p miRNA simulator (mimic) on the 8th, 10th, and 12th days after melanoma B-16 cell transplantation. Based on the results of bioinformatic analysis, miR-204-5p target genes BCL2 and SIRT1 expression levels were determined by quantitative real-time PCR. The toxic effect of miR-204-5p mimic was estimated by the evaluation of body weight, mass of the internal organs, and motor activity. Results. On the 13-14th days of the experiment, the motor activity of animals in the control groups decreased signifcantly compared to the group of animals treated by miR-204-5p. Target gene BCL2 showed increased expression in the lungs and kidneys and SIRT1 levels were increased in the lungs of miR-204-5p mimic treated animals (p˂0.05). Tumor mass tended to decrease in the animals treated by miR-204-5p mimic. Conclusion. Modulation of the level of miR-204-5p microRNA led to changes in the expression of SIRT1 and BCL2 in the lungs of animals, and changes in the expression of BCL2in the kidneys. MiR-204-5p mimic application did not have toxic effect on animals treated. Further studies are necessary to clarify miR-204-5p implication in melanoma cell proliferation regulation as well as it’s biodistibution in the tumor tissue.
19 September 2022 in Bulletin "Biomedicine and sociology"
Background: Penetration of plasmid DNA into the nucleus by a passive process is ineffective due to the barrier effect of lipid membranes and diffusion barriers inside the cell. An effective gene delivery system should ensure binding to the target cell, penetration by endocytosis, protection from degradation and, ultimately, delivery of the expression plasmid to the nucleus. The distribution routes of transfected agents play a crucial role in achieving the targeted effect of drugs. In our experiment, plasmid DNA of the reporter protein GFP was used to study the distribution pathways. Aim: to evaluate the distribution of GFP reporter protein in B16 melanoma cells and distant organs of C57Bl6 mice as a method for determining the effectiveness of transfection of genetically engineered structures for the diagnosis and therapy of tumors in vivo. Materials and methods: An in vitro study was conducted on skin melanoma cell lines B16. Cells were transfected with a plasmid of the reporter protein GFP. In vivo, the study was conducted on mature female mice of the C57Bl/6 line, to which tumor cells were transplanted and GFP plasmid was intraperitoneally injected using commercial transfectants Lipofectamine 3.0 and Invivofectamine. The efficiency of transfection in organ and tumor cells was evaluated using the cell imaging station Floid. Results: A high survival rate of B16 melanoma cells was established and GFP+ B16 melanoma cells were obtained within 48 hours. We found that with intraperitoneal administration of a lipocomplex containing GFP plasmid, both with the use of Lipofectamine 3.0 transfectant and Invivofectamine, effective incorporation into liver and kidney parenchyma cells occurs. The penetration and retention of GFP reporter protein in liver, kidney and tumor node cells was revealed. Conclusion: The effectiveness of transfection of GFP plasmid into liver, kidney, and melanoma B16 tumor node cells of C57Bl6 mice has been proven. The data obtained indicate the prospects for the use of transfecting agents for penetration into target cells of genetically engineered structures for the purpose of diagnosis and therapy of tumors in vivo.
12 February 2025 in Advanced Pharmaceutical Bulletin
Purpose: The present study aimed to determine the selective effects of BRAF V600E inhibitor on focal adhesion in melanoma cells with respect to their phenotypic reprogramming. Methods: Flow cytometry was used to analyse the distribution of BRAFV600E and BRAFWT melanoma cells throughout the cell cycle post-vemurafenib treatment. Senescent cells were identified based on b-galactosidase activity and the mRNA expression of cell cycle proteins, CCND1 and RBL1. Centrifugal cell adhesion assay was used to determine the adhesive capacities of resting and proliferative BRAF mutant and BRAF wild-type melanoma cells under vemurafenib treatment. Fibronectin binding was evaluated by spectrophotometry and quantitative real-time PCR to measure the mRNA levels of integrins: ITGAV, ITGA5, ITGB1 and ITGB3. Results: Vemurafenib increases the proportion of melanoma BRAFV600E-positive cells in the G0 phase of a cell cycle. Melanoma cells entering the G0 phase after vemurafenib treatment indicated an upregulation of senescence-associated markers. Non-proliferating melanoma cell number was elevated among vemurafenib-treated BRAFV600E cells with enhanced attachment. BRAFV600E-positive but not BRAFV600E-negative cells were characterised by upregulated ITGAV. Conclusion: The current results demonstrated that vemurafenib induces the phenotypic switch in melanoma cells depending on their mutational status. It also strengthens the adhesive features of senescent cells, increasing their binding to fibronectin via ITGAV, which may be a part of the phenotypic mode of drug resistance or slow interaction of proliferating cancer cells with the extracellular matrix. Thus, targeting senescent cells by focal adhesion modulators may be a promising approach to control drug-resistant melanoma cells.